Compare Enveric Biosciences Inc (ENVB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while State Street SPDR S&P Biotech ETF trades at $149.99 (market cap $10.08B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 1506.7× Enveric Biosciences Inc's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| ENVB | XBI | |
|---|---|---|
Market Cap | $6.69M | $10.08B |
Volume | 41,141 | 9,534,635 |
Sector | Health | Broad Market / Factor |
52-Week High | $10.80 | $169.55 |
52-Week Low | $1.27 | $104.99 |
Typical Hold Time | 14 Days | 37 Days |
Enterprise Value | -$1.60M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
XBI trades at $150.23, down 0.44% on the day, with bearish technical signals dominating. The ETF faces resistance near $152-154 while finding support at $147-149 levels. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech sector optimism from M&A activity and cancer vaccine breakthroughs. The fund's 0.35% expense ratio compares unfavorably to broader healthcare ETFs but offers targeted biotech exposure.
Outlook remains mixed with technical weakness offset by sector catalysts. The biotech focus provides growth potential but carries higher volatility than diversified healthcare alternatives. Key risks include sector-specific regulatory pressures and the fund's expense structure, while opportunities exist from ongoing pharmaceutical innovation and capital market improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
